Kalaris Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Atillasoy Ercem | See Remarks | Purchase | 3,500 | $17.00 | $59,500 | 78,500 | Aug 3, 2020 |
| Brainard Diana | — | Purchase | 6,300 | $17.00 | $107,100 | 6,300 | Aug 3, 2020 |
| ElevateBio, LLC | — | C | 13,420,970 | — | — | 13,420,970 | Aug 3, 2020 |
| GADICKE ANSBERT | — | C | 13,420,970 | — | — | 13,420,970 | Aug 3, 2020 |
| Hagen Brett R | Chief Accounting Officer | C | 4,361 | — | — | 54,176 | Aug 3, 2020 |
| VAN BEEK JEROEN B | Chief Commercial Officer | C | 6,710 | — | — | 521,640 | Aug 3, 2020 |
| Brenner Malcolm | — | C | 1,018,663 | — | — | 1,018,663 | Aug 3, 2020 |
| Hallal David | Chief Executive Officer | C | 738,153 | — | — | 738,153 | Aug 3, 2020 |
| Sinha Vikas | See Remarks | C | 13,420,970 | — | — | 13,420,970 | Aug 3, 2020 |
| Jovan-Embiricos Morana | — | Purchase | 100,000 | $17.00 | $1,700,000 | 347,011 | Aug 3, 2020 |
| Leen Ann M. | Chief Scientific Officer | C | 2,436,773 | — | — | 2,436,773 | Aug 3, 2020 |
| Miller Edward | General Counsel | C | 32,759 | — | — | 32,759 | Aug 3, 2020 |
| Bornstein Jeffrey S | — | C | 20,583 | — | — | 20,583 | Aug 3, 2020 |
| Wilson John Robert | — | C | 2,347,999 | — | — | 5,562,954 | Aug 3, 2020 |
| Vera Juan | — | C | 2,436,773 | — | — | 2,466,970 | Aug 3, 2020 |
| Atillasoy Ercem | See Remarks | Award / Grant | 75,000 | — | — | 75,000 | Jul 29, 2020 |